% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brieger:157048,
      author       = {K. K. Brieger and S. Peterson and A. W. Lee and B.
                      Mukherjee and K. M. Bakulski and A. Alimujiang and H.
                      Anton-Culver and M. S. Anglesio and E. V. Bandera and A.
                      Berchuck and D. D. L. Bowtell and G. Chenevix-Trench and K.
                      R. Cho and D. W. Cramer and A. DeFazio and J. A. Doherty and
                      R. T. Fortner$^*$ and D. W. Garsed and S. A. Gayther and A.
                      Gentry-Maharaj and E. L. Goode and M. T. Goodman and H. R.
                      Harris and E. Høgdall and D. G. Huntsman and H. Shen and A.
                      Jensen and S. E. Johnatty and S. J. Jordan and S. K. Kjaer
                      and J. Kupryjanczyk and D. Lambrechts and K. McLean and U.
                      Menon and F. Modugno and K. Moysich and R. Ness and S. J.
                      Ramus and J. Richardson and H. Risch and M. A. Rossing and
                      B. Trabert and N. Wentzensen and A. Ziogas and K. L. Terry
                      and A. H. Wu and G. E. Hanley and P. Pharoah and P. M. Webb
                      and M. C. Pike and C. L. Pearce},
      collaboration = {O. C. A. Consortium},
      title        = {{M}enopausal hormone therapy prior to the diagnosis of
                      ovarian cancer is associated with improved survival.},
      journal      = {Gynecologic oncology},
      volume       = {153},
      number       = {3},
      issn         = {0090-8258},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2020-01339},
      pages        = {702-709},
      year         = {2020},
      note         = {2020 Sep;158(3):702-709},
      abstract     = {Prior studies of menopausal hormone therapy (MHT) and
                      ovarian cancer survival have been limited by lack of hormone
                      regimen detail and insufficient sample sizes. To address
                      these limitations, a comprehensive analysis of 6419
                      post-menopausal women with pathologically confirmed ovarian
                      carcinoma was conducted to examine the association between
                      MHT use prior to diagnosis and survival.Data from 15 studies
                      in the Ovarian Cancer Association Consortium were included.
                      MHT use was examined by type (estrogen-only (ET) or
                      estrogen+progestin (EPT)), duration, and recency of use
                      relative to diagnosis. Cox proportional hazards models were
                      used to estimate the association between hormone therapy use
                      and survival. Logistic regression and mediation analysis was
                      used to explore the relationship between MHT use and
                      residual disease following debulking surgery.Use of ET or
                      EPT for at least five years prior to diagnosis was
                      associated with better ovarian cancer survival (hazard
                      ratio, 0.80; $95\%$ CI, 0.74 to 0.87). Among women with
                      advanced stage, high-grade serous carcinoma, those who used
                      MHT were less likely to have any macroscopic residual
                      disease at the time of primary debulking surgery (p for
                      trend <0.01 for duration of MHT use). Residual disease
                      mediated some $(17\%)$ of the relationship between MHT and
                      survival.Pre-diagnosis MHT use for 5+ years was a favorable
                      prognostic factor for women with ovarian cancer. This large
                      study is consistent with prior smaller studies, and further
                      work is needed to understand the underlying mechanism.},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32641237},
      doi          = {10.1016/j.ygyno.2020.06.481},
      url          = {https://inrepo02.dkfz.de/record/157048},
}